top of page
Science Lab

H.E.R. IVF

Technique

In HER IVF, a potential protocol for total cytoplasm replacement is to conduct sequential GVT and ST [19, 33, 37, 39, 41, 45]. First, a germinal vesicle from an oocyte containing high levels of pathogenic mtDNA is transferred to an enucleated, healthy donor oocyte (also at GV stage). The reconstructed GV is then allowed to undergo in vitro maturation (IVM) to reach the MII stage [78-83]. This can take up to two days of culture and is marked by the appearance of a polar body. Both nuclear and cytoplasmic maturity are required, however, for the successful progression of the MII oocyte to the blastocyst stage. When the MII stage is reached, and the birefringent spindle is visible, the cytoplasm is replaced again with a cytoplasm from a stage-matched in vivo MII (an oocyte which has not been in prolonged culture) [37].

Germinal Vesicle NT
gv-nuclear-transfer.png

Conducting a second transfer after GVT ensures that the reconstructed MII has functional components to successfully complete the remaining preimplantation development [17, 18, 37, 44]. Most importantly, however, the second nuclear transfer ensures that any carryover, however small, from the first NT is diluted in the new donor cytoplasm. The well documented <2% carryover from ST ensures a close to zero chance of picking up pathogenic mtDNA persisting from the first nuclear transfer. The total cytoplasm replacement is necessary to ensure that no carried over pathogenic mtDNA would have the opportunity to be selected for preferential replication and expand during development of the reconstituted embryo.

HER-IVF-SEQUENTIAL-NUCLEAR-TRANSFER.png

784 Park Avenue, New York, NY 10019

hovey.li@nhfc.com

917-546-9890

The information contained on this site is intended for informational purposes only.

Please be advised that MRT and IVF using MRT-modified oocytes is not performed in the United States, and has not been reviewed by the U.S. Food and Drug Administration. Also, due to its experimental nature, limited use to date, and other variables, we cannot guarantee procedures will result in successful outcomes and healthy children. Darwin Life operates to conduct IRB-approved basic research within the regulations of a research license, and the company will not conduct any clinical work in USA for the foreseeable future.

Copyright 2016-2025 Darwin Life. All Rights Reserved

bottom of page